Dare Bioscience (DARE) Net Shares Issued and Repurchased (2014 - 2018)
Dare Bioscience's (DARE) quarterly Net Shares Issued and Repurchased came in at $3500.0 in Q1 2018, down 99.76% on a YoY basis from $1.5 million in Q1 2017, and down 99.38% quarter-over-quarter from $565372.0 in Q4 2017.
Analysis
Dare Bioscience (DARE) Net Shares Issued and Repurchased (2014 - 2018) Analysis & Trends
Dare Bioscience (DARE) has reported Net Shares Issued and Repurchased for 5 consecutive years, with $3500.0 the latest figure, recorded in Q1 2018.
- For the quarter ending Q1 2018, Net Shares Issued and Repurchased fell 99.76% year-over-year to $3500.0; the trailing twelve-month figure through Mar 2018 stood at $3500.0 (down 99.76% YoY), and the FY2017 full-year result was $565372.0, down 64.61% from the prior year.
- Net Shares Issued and Repurchased fell to $3500.0 in Q1 2018 per DARE's latest filing, from $565372.0 in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $2.4 million in Q4 2015 and bottomed at $3500.0 in Q1 2018.
- Historically, Net Shares Issued and Repurchased has averaged $966027.1 across 5 years, with a median of $842820.0 in 2015.
- The sharpest annual moves came in 2015 and 2018: Net Shares Issued and Repurchased jumped 428.05% in 2015, then tumbled 99.76% in 2018.
- Over 5 years, Net Shares Issued and Repurchased stood at $1.1 million in 2014, then soared by 107.41% to $2.4 million in 2015, then plunged by 32.33% to $1.6 million in 2016, then tumbled by 64.61% to $565372.0 in 2017, then plunged by 99.38% to $3500.0 in 2018.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $3500.0, $565372.0, and $1.5 million for Q1 2018, Q4 2017, and Q1 2017 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Dare Bioscience | 10.92 Mn | -1.70 Mn | -132,343.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2018 | 3,500.00 |
| Dec 31, 2017 | 565,372.00 |
| Mar 31, 2017 | 1.48 Mn |
| Dec 31, 2016 | 1.60 Mn |
| Mar 31, 2016 | 547,070.00 |
| Dec 31, 2015 | 2.36 Mn |
| Mar 31, 2015 | 842,820.00 |
| Dec 31, 2014 | 1.14 Mn |
| Mar 31, 2014 | 159,610.00 |